Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2026-06-01 Report Publication Anno…
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The document is a formal stock exchange submission under SEBI LODR Regulation 30 dated June 1, 2026, stating “Publication of Audited Financial Results for the Quarter and Year ended March 31, 2026” and enclosing an extract of those results as published in newspapers. It does not itself contain complete financial statements but rather announces that the audited results have been published and are being filed with the exchanges. This matches our definition of a Report Publication Announcement (RPA).
2026-06-01 English
Newspaper Publication for the Audited Financial Results of the Company for the Quarter & Year ended March 31, 2026 as published in "Financial Express" and "Makkal Kural" on May 31, 2026.
Earnings Release Classification · 82% confidence The document is a stock‐exchange filing dated June 1, 2026 notifying the publication of audited quarterly and year‐end financial results under SEBI LODR Regulation 30 and enclosing the printed extract of those results (with key financial figures). It is not a full annual report (10‐K) nor merely a report‐publication notice – it contains the actual results. This matches an initial announcement of periodic financial results, i.e. an Earnings Release. FY 2026
2026-06-01 English
We herewith enclose the Audited Financial Results of the Company along with the Statutory Auditor''s Report for the Quarter and Year ended March 31, 2026, as approved by the Board of Directors ....
Interim / Quarterly Report Classification · 85% confidence The document is a board meeting outcome filed under Regulation 30 of SEBI LODR, containing the ‘Statement of Audited Financial Results’ for the quarter and year ended March 31, 2026, complete with P&L, balance sheet, cash flow statements, notes, and auditor’s report. This is a full, audited quarterly/interim report rather than a brief earnings release or full annual report. It matches the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-29 English
We hereby inform you that the Board of Directors in their meeting held on May 29, 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditor's ....
Interim / Quarterly Report Classification · 89% confidence The document is a Board meeting outcome filed under SEBI (LODR) Regulation 30/33, announcing and enclosing the Audited Financial Results (including full P&L, Balance Sheet, Cash Flow and Notes) for the quarter and year ended March 31, 2026 along with the Auditor’s Report. It goes well beyond a simple earnings highlight (ER) and is not a full narrative Annual Report (10-K), but rather the mandated quarterly/annual financial statements submission under SEBI regulations. This corresponds to an Interim/Quarterly Report category. FY 2026
2026-05-29 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 87% confidence The document is a stock‐exchange filing under SEBI LODR Reg.30 and Reg.33, containing the board’s approval of audited financial results for the quarter and year ended March 31, 2026, along with full P&L, balance sheet, cash flow statements, notes and the auditor’s report. It is not merely an earnings highlight or a short publication notice, and it is not a full annual report (10-K) or proxy. It contains substantive interim/quarterly financial data in accordance with IR/quarterly reporting requirements. Therefore, it classifies as an Interim/Quarterly Report. FY 2026
2026-05-29 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 90% confidence The document is a SEBI Regulation 31(4) disclosure by the promoter confirming no encumbrance on shares for the year ended March 31, 2026. This is a compliance/regulatory disclosure rather than a change in shareholding threshold or a financial report. It fits under general “Regulatory Filings” (SEBI filing) rather than Major Shareholding Notification (which is for threshold crossings) or other categories.
2026-05-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.